Would you offer adjuvant immune checkpoint therapy for a patient with resected mucosal melanoma with a tumor thickness >4.0 mm with negative LN involvement?

Although adjuvant therapy is an option for patients with thick cutaneous melanomas, based on the results of the KEYNOTE-716 clinical trial (as well as CheckMate76K clinical trials), these trials limited accruals to cutaneous melanoma patients only. Thus, the efficacy of adjuvant immune checkpoint th...